DuoGenic StemCells (ROCO:7607) Cash Ratio : 2.27 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. DuoGenic StemCells's Cash Ratio for the quarter that ended in Jun. 2024 was 2.27.

DuoGenic StemCells has a Cash Ratio of 2.27. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for DuoGenic StemCells's Cash Ratio or its related term are showing as below:

ROCO:7607' s Cash Ratio Range Over the Past 10 Years
Min: 2.27 Med: 6.13 Max: 13.72
Current: 2.27

During the past 3 years, DuoGenic StemCells's highest Cash Ratio was 13.72. The lowest was 2.27. And the median was 6.13.

ROCO:7607's Cash Ratio is ranked worse than
54.75% of 1474 companies
in the Biotechnology industry
Industry Median: 2.665 vs ROCO:7607: 2.27

DuoGenic StemCells Cash Ratio Historical Data

The historical data trend for DuoGenic StemCells's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells Cash Ratio Chart

DuoGenic StemCells Annual Data

Trend

Dec21

Dec22

Dec23

Cash Ratio

13.72

6.13

4.47

DuoGenic StemCells Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash Ratio	Get a 7-Day Free Trial			-	6.13	9.07	4.47	2.27

Competitive Comparison of DuoGenic StemCells's Cash Ratio

For the Biotechnology subindustry, DuoGenic StemCells's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Cash Ratio distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Cash Ratio falls into.

DuoGenic StemCells Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

DuoGenic StemCells's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	46.296	/	10.354
	=	4.47

DuoGenic StemCells's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	20.315	/	8.934
	=	2.27

DuoGenic StemCells (ROCO:7607) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.

DuoGenic StemCells Cash Ratio Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

DuoGenic StemCells Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Cash Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN

Website

https://www.dgsc.com.tw

DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines